GHK-Cu

GHK-Cu is a small peptide of three amino acids (glycine, histidine and lysine) bound to a copper ion. It occurs naturally in the body, and its level declines with age. It is used mainly as a cosmetic ingredient in serums and creams for skin and hair. Injectable GHK-Cu is not FDA-approved, and the FDA has flagged compounded injectable GHK-Cu for possible immune reactions.

The proven ones are small. A 2026 systematic review included only 2 randomized trials among its 20 studies. Clinically, the review reports that GHK-Cu improved patient-reported satisfaction after laser resurfacing and reduced wrinkle volume and depth compared with controls. Another 2026 review notes a 13-person laser study that was negative on objective measures, and calls GHK-Cu “promising but unproven.” For hair, it cites one 18-person eyebrow study with positive cosmetic outcomes and no measure of how much GHK-Cu reached the tissue; that is not evidence for treating hair loss. Lab and animal findings on collagen and wound repair have not been confirmed by adequate human trials.

No GHK-Cu drug is FDA-approved. Creams and serums are sold as cosmetics, which don’t need approval. For pharmacy compounding, the FDA removed non-injectable GHK-Cu from Category 1 on April 22, 2026 after its nominations were withdrawn; on May 5, 2026 one nominator said it meant to withdraw only the injectable route, so non-injectable GHK-Cu is back in Category 1. Category 1 is not approval: it means the FDA does not intend to take action against a compounder using the substance if the conditions in its guidance are met. The FDA plans to discuss GHK-Cu with its Pharmacy Compounding Advisory Committee before the end of February 2027. No date is set, and the committee’s recommendations are non-binding.

Yes, in law and in what is known. Under the FD&C Act, a product’s intended use decides whether it is a cosmetic or a drug: a cream sold to improve appearance is a cosmetic, while a product meant to affect the structure or function of the body is a drug, and the law has no “cosmeceutical” category. Injectable GHK-Cu was withdrawn from the FDA’s compounding lists, and the FDA flagged it for possible immune reactions from aggregation and impurities. Most of the limited human evidence is for products on the skin. If you have a powder vial, the GHK-Cu 50 mg calculator does the mixing arithmetic; for a blend vial, whose total mg is not all GHK-Cu, use the blend calculator.

There is little human safety data, especially for injections. The FDA has raised a possible risk of immune reactions with injectable GHK-Cu and notes limited human data. Researchers point out that products vary in how the copper is bound and how much free copper they release, which can affect toxicity. Stop any product that causes irritation, and talk to a clinician.

It has not been established in people. A 2026 review notes that studies usually don’t resolve whether a product releases intact GHK-Cu or free GHK and copper, and that stability and pharmacokinetics vary with the formulation. So a figure measured for one product would not carry over to another.